1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €265.62 (+25.23%). The median is €278.35 (+31.24%).
| Buy |
23 |
| Hold |
2 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 344.9M | 118.23% |
| Gross profit | 312.61M | 146.93% |
| Net profit | 210.4M | 641.49% |
| EBITDA | 68.08M | 2,835.57% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €13.29B |
Number of shares | 62.11M |
52-week high/low | €243.52 - €160.58 |
| Dividends | No |
Beta | 0.38 |
P/E ratio | 17.68 |
PEG ratio | 0.03 |
P/B ratio | 9.59 |
P/S ratio | 12.60 |
Company profile
| Name | Ascendis Pharma ADR |
| CEO | Jan Moller Mikkelsen |
| Employees | 1,189 |
Deep Dive
Discover assets
Shareholders of Ascendis Pharma ADR also invest in the following assets
